Overview: Lupus Anticoagulant APTT TestIntroduction: The Lupus Anticoagulant APTT Test detects lupus anticoagulant to diagnose clotting disorders, causing excessive bleeding or clots. Aligned with 2023 ASH guidelines, it uses biochemical methods for high specificity, supporting hematological screening. This test is critical for guiding diagnosis, treatment planning, and improving outcomes in coagulation for patients with suspected antiphospholipid syndrome.
Other Names: Lupus Anticoagulant Assay, APTT-Based Clotting Test.
FDA Status: Laboratory-developed test (LDT), meeting coagulation standards for diagnostic accuracy.
Historical Milestone: Lupus anticoagulant testing began in the 1980s with antiphospholipid syndrome research. APTT-based methods improved in the 2000s, enhancing diagnostic precision.
Purpose: Detects lupus anticoagulant to diagnose clotting disorders, guides treatment, and evaluates patients with excessive bleeding or clots.
Test Parameters: 1. Lupus Anticoagulant
Pretest Condition: No fasting required. Collect plasma. Report history of bleeding, clots, or autoimmune diseases.
Specimen: Plasma (NaCit, 2-4 mL). Transport in a biohazard container.
Sample Stability at Room Temperature: 24 hours
Sample Stability at Refrigeration: 5 days
Sample Stability at Frozen: Not frozen
Medical History: Document bleeding, clots, miscarriages, or family history of autoimmune diseases. Include current medications, especially anticoagulants.
Consent: Written consent required, detailing the tests purpose, clotting disorder implications, and risks of blood collection.
Procedural Considerations: Uses biochemical methods (e.g., APTT) to detect lupus anticoagulant in plasma. Results are available in 1-2 days, supporting rapid clinical decisions. Performed in laboratories, often for antiphospholipid syndrome diagnosis.
Factors Affecting Result Accuracy: Improper anticoagulant ratio or sample storage can affect results. Heparin contamination may reduce accuracy.
Clinical Significance: Positive lupus anticoagulant confirms antiphospholipid syndrome, guiding anticoagulation therapy. Negative results may require further coagulation testing.
Specialist Consultation: Consult a hematologist for result interpretation and treatment planning.
Additional Supporting Tests: Anticardiolipin antibodies, beta-2 glycoprotein antibodies, or dRVVT to confirm antiphospholipid syndrome.
Test Limitations: Not specific to antiphospholipid syndrome; other clotting disorders may affect results. Clinical correlation is needed.
References: ASH Antiphospholipid Guidelines, 2023; Blood, Cohen H, 2022.
